EF Hutton says there is a significant outbreak of clade I mpox in the Democratic Republic of the Congo that is spreading to neighboring countries such as the Republic of the Congo, Central African Republic, Burundi, Rwanda, and Uganda. GeoVax Labs has a traditional monkey pox modified vaccinia ankara vaccine program and the U.S. Government is discussing the program with the company, the analyst tells investors in a research note. The firm says the company has partnered with Oxford Biomedica, which has a successful track record as a contract manufacturer with this type of vaccine. EF does not forecast any revenues for monkey pox but recognizes that as the government talks with GeoVax, the program could rise in importance. It views this as positive for the company. The firm has a Buy rating on GeoVax with an $18 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOVX:
- Siga slides, GeoVax jumps after mpox study shows limited effectiveness
- GeoVax to Present at the Emerging Growth Conference on August 21, 2024
- GeoVax shares jump after after Siga mpox study failure
- Siga, GeoVax rally after WHO declares mpox global emergency
- GeoVax Labs appoints Lambe to Scientific Advisory Board